nodes	percent_of_prediction	percent_of_DWPC	metapath
Dihydroergotamine—HTR1A—stomach cancer	0.545	1	CbGaD
Dihydroergotamine—ABCB1—Mitomycin—stomach cancer	0.0899	0.483	CbGbCtD
Dihydroergotamine—ABCB1—Irinotecan—stomach cancer	0.0231	0.124	CbGbCtD
Dihydroergotamine—ABCB1—Docetaxel—stomach cancer	0.0169	0.0908	CbGbCtD
Dihydroergotamine—CYP3A4—Irinotecan—stomach cancer	0.0138	0.0742	CbGbCtD
Dihydroergotamine—ABCB1—Doxorubicin—stomach cancer	0.0126	0.0677	CbGbCtD
Dihydroergotamine—ABCB1—Methotrexate—stomach cancer	0.0122	0.0656	CbGbCtD
Dihydroergotamine—CYP3A4—Docetaxel—stomach cancer	0.0101	0.0544	CbGbCtD
Dihydroergotamine—CYP3A4—Doxorubicin—stomach cancer	0.00755	0.0406	CbGbCtD
Dihydroergotamine—Bromocriptine—ADRB1—stomach cancer	0.00102	0.354	CrCbGaD
Dihydroergotamine—Ergotamine—HTR1A—stomach cancer	0.000948	0.329	CrCbGaD
Dihydroergotamine—Bromocriptine—HTR1A—stomach cancer	0.000914	0.317	CrCbGaD
Dihydroergotamine—Ill-defined disorder—Capecitabine—stomach cancer	0.000242	0.00131	CcSEcCtD
Dihydroergotamine—Urticaria—Fluorouracil—stomach cancer	0.000242	0.00131	CcSEcCtD
Dihydroergotamine—Conjunctivitis—Methotrexate—stomach cancer	0.000242	0.00131	CcSEcCtD
Dihydroergotamine—Dysphagia—Doxorubicin—stomach cancer	0.000242	0.00131	CcSEcCtD
Dihydroergotamine—Pollakiuria—Epirubicin—stomach cancer	0.000241	0.00131	CcSEcCtD
Dihydroergotamine—Body temperature increased—Fluorouracil—stomach cancer	0.000241	0.00131	CcSEcCtD
Dihydroergotamine—Palpitations—Docetaxel—stomach cancer	0.000238	0.00129	CcSEcCtD
Dihydroergotamine—Malaise—Capecitabine—stomach cancer	0.000235	0.00128	CcSEcCtD
Dihydroergotamine—Angina pectoris—Doxorubicin—stomach cancer	0.000235	0.00128	CcSEcCtD
Dihydroergotamine—Epistaxis—Methotrexate—stomach cancer	0.000235	0.00127	CcSEcCtD
Dihydroergotamine—Vertigo—Capecitabine—stomach cancer	0.000235	0.00127	CcSEcCtD
Dihydroergotamine—Hypersensitivity—Irinotecan—stomach cancer	0.000235	0.00127	CcSEcCtD
Dihydroergotamine—Hypertension—Docetaxel—stomach cancer	0.000233	0.00126	CcSEcCtD
Dihydroergotamine—Bronchitis—Doxorubicin—stomach cancer	0.000232	0.00126	CcSEcCtD
Dihydroergotamine—Palpitations—Capecitabine—stomach cancer	0.000231	0.00125	CcSEcCtD
Dihydroergotamine—Arthralgia—Docetaxel—stomach cancer	0.00023	0.00125	CcSEcCtD
Dihydroergotamine—Myalgia—Docetaxel—stomach cancer	0.00023	0.00125	CcSEcCtD
Dihydroergotamine—Asthenia—Irinotecan—stomach cancer	0.000228	0.00124	CcSEcCtD
Dihydroergotamine—Conjunctivitis—Epirubicin—stomach cancer	0.000226	0.00123	CcSEcCtD
Dihydroergotamine—Hypertension—Capecitabine—stomach cancer	0.000225	0.00122	CcSEcCtD
Dihydroergotamine—Hypersensitivity—Fluorouracil—stomach cancer	0.000225	0.00122	CcSEcCtD
Dihydroergotamine—Dry mouth—Docetaxel—stomach cancer	0.000225	0.00122	CcSEcCtD
Dihydroergotamine—Upper respiratory tract infection—Doxorubicin—stomach cancer	0.000225	0.00122	CcSEcCtD
Dihydroergotamine—Pollakiuria—Doxorubicin—stomach cancer	0.000223	0.00121	CcSEcCtD
Dihydroergotamine—Myalgia—Capecitabine—stomach cancer	0.000222	0.00121	CcSEcCtD
Dihydroergotamine—Arthralgia—Capecitabine—stomach cancer	0.000222	0.00121	CcSEcCtD
Dihydroergotamine—Confusional state—Docetaxel—stomach cancer	0.000222	0.0012	CcSEcCtD
Dihydroergotamine—Pharyngitis—Methotrexate—stomach cancer	0.000222	0.0012	CcSEcCtD
Dihydroergotamine—Anxiety—Capecitabine—stomach cancer	0.000222	0.0012	CcSEcCtD
Dihydroergotamine—Oedema—Docetaxel—stomach cancer	0.00022	0.00119	CcSEcCtD
Dihydroergotamine—Discomfort—Capecitabine—stomach cancer	0.00022	0.00119	CcSEcCtD
Dihydroergotamine—Epistaxis—Epirubicin—stomach cancer	0.00022	0.00119	CcSEcCtD
Dihydroergotamine—Sinusitis—Epirubicin—stomach cancer	0.000218	0.00118	CcSEcCtD
Dihydroergotamine—Diarrhoea—Irinotecan—stomach cancer	0.000218	0.00118	CcSEcCtD
Dihydroergotamine—Dry mouth—Capecitabine—stomach cancer	0.000217	0.00118	CcSEcCtD
Dihydroergotamine—Shock—Docetaxel—stomach cancer	0.000217	0.00117	CcSEcCtD
Dihydroergotamine—Pruritus—Fluorouracil—stomach cancer	0.000216	0.00117	CcSEcCtD
Dihydroergotamine—Visual impairment—Methotrexate—stomach cancer	0.000215	0.00117	CcSEcCtD
Dihydroergotamine—Confusional state—Capecitabine—stomach cancer	0.000215	0.00117	CcSEcCtD
Dihydroergotamine—Tachycardia—Docetaxel—stomach cancer	0.000215	0.00117	CcSEcCtD
Dihydroergotamine—Oedema—Capecitabine—stomach cancer	0.000213	0.00116	CcSEcCtD
Dihydroergotamine—Dizziness—Irinotecan—stomach cancer	0.000211	0.00114	CcSEcCtD
Dihydroergotamine—Anorexia—Docetaxel—stomach cancer	0.00021	0.00114	CcSEcCtD
Dihydroergotamine—Shock—Capecitabine—stomach cancer	0.00021	0.00114	CcSEcCtD
Dihydroergotamine—Rhinitis—Epirubicin—stomach cancer	0.00021	0.00114	CcSEcCtD
Dihydroergotamine—Conjunctivitis—Doxorubicin—stomach cancer	0.000209	0.00114	CcSEcCtD
Dihydroergotamine—Diarrhoea—Fluorouracil—stomach cancer	0.000209	0.00113	CcSEcCtD
Dihydroergotamine—Tinnitus—Methotrexate—stomach cancer	0.000208	0.00113	CcSEcCtD
Dihydroergotamine—Tachycardia—Capecitabine—stomach cancer	0.000208	0.00113	CcSEcCtD
Dihydroergotamine—Hypoaesthesia—Epirubicin—stomach cancer	0.000208	0.00113	CcSEcCtD
Dihydroergotamine—Pharyngitis—Epirubicin—stomach cancer	0.000207	0.00113	CcSEcCtD
Dihydroergotamine—Hyperhidrosis—Capecitabine—stomach cancer	0.000206	0.00112	CcSEcCtD
Dihydroergotamine—Hypotension—Docetaxel—stomach cancer	0.000206	0.00112	CcSEcCtD
Dihydroergotamine—Epistaxis—Doxorubicin—stomach cancer	0.000203	0.0011	CcSEcCtD
Dihydroergotamine—Anorexia—Capecitabine—stomach cancer	0.000203	0.0011	CcSEcCtD
Dihydroergotamine—Vomiting—Irinotecan—stomach cancer	0.000202	0.0011	CcSEcCtD
Dihydroergotamine—Sinusitis—Doxorubicin—stomach cancer	0.000202	0.0011	CcSEcCtD
Dihydroergotamine—Dizziness—Fluorouracil—stomach cancer	0.000202	0.00109	CcSEcCtD
Dihydroergotamine—Visual impairment—Epirubicin—stomach cancer	0.000201	0.00109	CcSEcCtD
Dihydroergotamine—Rash—Irinotecan—stomach cancer	0.000201	0.00109	CcSEcCtD
Dihydroergotamine—Dermatitis—Irinotecan—stomach cancer	0.000201	0.00109	CcSEcCtD
Dihydroergotamine—Musculoskeletal discomfort—Docetaxel—stomach cancer	0.000201	0.00109	CcSEcCtD
Dihydroergotamine—Chills—Methotrexate—stomach cancer	0.0002	0.00109	CcSEcCtD
Dihydroergotamine—Headache—Irinotecan—stomach cancer	0.000199	0.00108	CcSEcCtD
Dihydroergotamine—Hypotension—Capecitabine—stomach cancer	0.000199	0.00108	CcSEcCtD
Dihydroergotamine—Insomnia—Docetaxel—stomach cancer	0.000199	0.00108	CcSEcCtD
Dihydroergotamine—Paraesthesia—Docetaxel—stomach cancer	0.000198	0.00107	CcSEcCtD
Dihydroergotamine—Dyspnoea—Docetaxel—stomach cancer	0.000196	0.00106	CcSEcCtD
Dihydroergotamine—Somnolence—Docetaxel—stomach cancer	0.000196	0.00106	CcSEcCtD
Dihydroergotamine—Tinnitus—Epirubicin—stomach cancer	0.000195	0.00106	CcSEcCtD
Dihydroergotamine—Musculoskeletal discomfort—Capecitabine—stomach cancer	0.000194	0.00105	CcSEcCtD
Dihydroergotamine—Flushing—Epirubicin—stomach cancer	0.000194	0.00105	CcSEcCtD
Dihydroergotamine—Vomiting—Fluorouracil—stomach cancer	0.000194	0.00105	CcSEcCtD
Dihydroergotamine—Rhinitis—Doxorubicin—stomach cancer	0.000194	0.00105	CcSEcCtD
Dihydroergotamine—Dyspepsia—Docetaxel—stomach cancer	0.000194	0.00105	CcSEcCtD
Dihydroergotamine—Insomnia—Capecitabine—stomach cancer	0.000193	0.00105	CcSEcCtD
Dihydroergotamine—Hypoaesthesia—Doxorubicin—stomach cancer	0.000192	0.00104	CcSEcCtD
Dihydroergotamine—Rash—Fluorouracil—stomach cancer	0.000192	0.00104	CcSEcCtD
Dihydroergotamine—Dermatitis—Fluorouracil—stomach cancer	0.000192	0.00104	CcSEcCtD
Dihydroergotamine—Pharyngitis—Doxorubicin—stomach cancer	0.000192	0.00104	CcSEcCtD
Dihydroergotamine—Paraesthesia—Capecitabine—stomach cancer	0.000191	0.00104	CcSEcCtD
Dihydroergotamine—Decreased appetite—Docetaxel—stomach cancer	0.000191	0.00104	CcSEcCtD
Dihydroergotamine—Headache—Fluorouracil—stomach cancer	0.000191	0.00104	CcSEcCtD
Dihydroergotamine—Dyspnoea—Capecitabine—stomach cancer	0.00019	0.00103	CcSEcCtD
Dihydroergotamine—Fatigue—Docetaxel—stomach cancer	0.00019	0.00103	CcSEcCtD
Dihydroergotamine—Nausea—Irinotecan—stomach cancer	0.000189	0.00103	CcSEcCtD
Dihydroergotamine—Pain—Docetaxel—stomach cancer	0.000188	0.00102	CcSEcCtD
Dihydroergotamine—Dyspepsia—Capecitabine—stomach cancer	0.000188	0.00102	CcSEcCtD
Dihydroergotamine—Chills—Epirubicin—stomach cancer	0.000188	0.00102	CcSEcCtD
Dihydroergotamine—Visual impairment—Doxorubicin—stomach cancer	0.000186	0.00101	CcSEcCtD
Dihydroergotamine—Decreased appetite—Capecitabine—stomach cancer	0.000185	0.00101	CcSEcCtD
Dihydroergotamine—Fatigue—Capecitabine—stomach cancer	0.000184	0.000997	CcSEcCtD
Dihydroergotamine—Pain—Capecitabine—stomach cancer	0.000182	0.000989	CcSEcCtD
Dihydroergotamine—Feeling abnormal—Docetaxel—stomach cancer	0.000181	0.000984	CcSEcCtD
Dihydroergotamine—Nausea—Fluorouracil—stomach cancer	0.000181	0.000983	CcSEcCtD
Dihydroergotamine—Ill-defined disorder—Methotrexate—stomach cancer	0.00018	0.000978	CcSEcCtD
Dihydroergotamine—Tinnitus—Doxorubicin—stomach cancer	0.00018	0.000978	CcSEcCtD
Dihydroergotamine—Gastrointestinal pain—Docetaxel—stomach cancer	0.00018	0.000976	CcSEcCtD
Dihydroergotamine—Flushing—Doxorubicin—stomach cancer	0.000179	0.000974	CcSEcCtD
Dihydroergotamine—Tension—Epirubicin—stomach cancer	0.000179	0.000968	CcSEcCtD
Dihydroergotamine—Nervousness—Epirubicin—stomach cancer	0.000177	0.000959	CcSEcCtD
Dihydroergotamine—Feeling abnormal—Capecitabine—stomach cancer	0.000176	0.000953	CcSEcCtD
Dihydroergotamine—Malaise—Methotrexate—stomach cancer	0.000175	0.000951	CcSEcCtD
Dihydroergotamine—Muscle spasms—Epirubicin—stomach cancer	0.000175	0.000949	CcSEcCtD
Dihydroergotamine—Vertigo—Methotrexate—stomach cancer	0.000175	0.000947	CcSEcCtD
Dihydroergotamine—Gastrointestinal pain—Capecitabine—stomach cancer	0.000174	0.000945	CcSEcCtD
Dihydroergotamine—Abdominal pain—Docetaxel—stomach cancer	0.000174	0.000944	CcSEcCtD
Dihydroergotamine—Body temperature increased—Docetaxel—stomach cancer	0.000174	0.000944	CcSEcCtD
Dihydroergotamine—Chills—Doxorubicin—stomach cancer	0.000173	0.000941	CcSEcCtD
Dihydroergotamine—Urticaria—Capecitabine—stomach cancer	0.000169	0.000918	CcSEcCtD
Dihydroergotamine—Ill-defined disorder—Epirubicin—stomach cancer	0.000169	0.000916	CcSEcCtD
Dihydroergotamine—Body temperature increased—Capecitabine—stomach cancer	0.000168	0.000914	CcSEcCtD
Dihydroergotamine—Abdominal pain—Capecitabine—stomach cancer	0.000168	0.000914	CcSEcCtD
Dihydroergotamine—Agitation—Epirubicin—stomach cancer	0.000167	0.000907	CcSEcCtD
Dihydroergotamine—Myalgia—Methotrexate—stomach cancer	0.000165	0.000898	CcSEcCtD
Dihydroergotamine—Arthralgia—Methotrexate—stomach cancer	0.000165	0.000898	CcSEcCtD
Dihydroergotamine—Tension—Doxorubicin—stomach cancer	0.000165	0.000896	CcSEcCtD
Dihydroergotamine—Malaise—Epirubicin—stomach cancer	0.000164	0.00089	CcSEcCtD
Dihydroergotamine—Discomfort—Methotrexate—stomach cancer	0.000164	0.000887	CcSEcCtD
Dihydroergotamine—Nervousness—Doxorubicin—stomach cancer	0.000163	0.000887	CcSEcCtD
Dihydroergotamine—Vertigo—Epirubicin—stomach cancer	0.000163	0.000887	CcSEcCtD
Dihydroergotamine—Hypersensitivity—Docetaxel—stomach cancer	0.000162	0.00088	CcSEcCtD
Dihydroergotamine—Muscle spasms—Doxorubicin—stomach cancer	0.000162	0.000878	CcSEcCtD
Dihydroergotamine—Palpitations—Epirubicin—stomach cancer	0.000161	0.000872	CcSEcCtD
Dihydroergotamine—Confusional state—Methotrexate—stomach cancer	0.00016	0.000868	CcSEcCtD
Dihydroergotamine—Asthenia—Docetaxel—stomach cancer	0.000158	0.000857	CcSEcCtD
Dihydroergotamine—Hypertension—Epirubicin—stomach cancer	0.000157	0.000852	CcSEcCtD
Dihydroergotamine—Hypersensitivity—Capecitabine—stomach cancer	0.000157	0.000852	CcSEcCtD
Dihydroergotamine—Ill-defined disorder—Doxorubicin—stomach cancer	0.000156	0.000847	CcSEcCtD
Dihydroergotamine—Pruritus—Docetaxel—stomach cancer	0.000156	0.000845	CcSEcCtD
Dihydroergotamine—Arthralgia—Epirubicin—stomach cancer	0.000155	0.00084	CcSEcCtD
Dihydroergotamine—Myalgia—Epirubicin—stomach cancer	0.000155	0.00084	CcSEcCtD
Dihydroergotamine—Agitation—Doxorubicin—stomach cancer	0.000155	0.000839	CcSEcCtD
Dihydroergotamine—Anxiety—Epirubicin—stomach cancer	0.000154	0.000837	CcSEcCtD
Dihydroergotamine—Hyperhidrosis—Methotrexate—stomach cancer	0.000153	0.000832	CcSEcCtD
Dihydroergotamine—Discomfort—Epirubicin—stomach cancer	0.000153	0.00083	CcSEcCtD
Dihydroergotamine—Asthenia—Capecitabine—stomach cancer	0.000153	0.00083	CcSEcCtD
Dihydroergotamine—Malaise—Doxorubicin—stomach cancer	0.000152	0.000823	CcSEcCtD
Dihydroergotamine—Dry mouth—Epirubicin—stomach cancer	0.000151	0.000822	CcSEcCtD
Dihydroergotamine—Vertigo—Doxorubicin—stomach cancer	0.000151	0.00082	CcSEcCtD
Dihydroergotamine—Anorexia—Methotrexate—stomach cancer	0.000151	0.00082	CcSEcCtD
Dihydroergotamine—Pruritus—Capecitabine—stomach cancer	0.000151	0.000818	CcSEcCtD
Dihydroergotamine—Diarrhoea—Docetaxel—stomach cancer	0.000151	0.000817	CcSEcCtD
Dihydroergotamine—Confusional state—Epirubicin—stomach cancer	0.00015	0.000812	CcSEcCtD
Dihydroergotamine—Palpitations—Doxorubicin—stomach cancer	0.000149	0.000807	CcSEcCtD
Dihydroergotamine—Oedema—Epirubicin—stomach cancer	0.000148	0.000805	CcSEcCtD
Dihydroergotamine—Hypotension—Methotrexate—stomach cancer	0.000148	0.000804	CcSEcCtD
Dihydroergotamine—Shock—Epirubicin—stomach cancer	0.000146	0.000792	CcSEcCtD
Dihydroergotamine—Diarrhoea—Capecitabine—stomach cancer	0.000146	0.000791	CcSEcCtD
Dihydroergotamine—Dizziness—Docetaxel—stomach cancer	0.000146	0.00079	CcSEcCtD
Dihydroergotamine—Hypertension—Doxorubicin—stomach cancer	0.000145	0.000788	CcSEcCtD
Dihydroergotamine—Tachycardia—Epirubicin—stomach cancer	0.000145	0.000786	CcSEcCtD
Dihydroergotamine—Musculoskeletal discomfort—Methotrexate—stomach cancer	0.000145	0.000784	CcSEcCtD
Dihydroergotamine—Hyperhidrosis—Epirubicin—stomach cancer	0.000144	0.000779	CcSEcCtD
Dihydroergotamine—Insomnia—Methotrexate—stomach cancer	0.000143	0.000778	CcSEcCtD
Dihydroergotamine—Myalgia—Doxorubicin—stomach cancer	0.000143	0.000777	CcSEcCtD
Dihydroergotamine—Arthralgia—Doxorubicin—stomach cancer	0.000143	0.000777	CcSEcCtD
Dihydroergotamine—Anxiety—Doxorubicin—stomach cancer	0.000143	0.000775	CcSEcCtD
Dihydroergotamine—Paraesthesia—Methotrexate—stomach cancer	0.000142	0.000773	CcSEcCtD
Dihydroergotamine—Discomfort—Doxorubicin—stomach cancer	0.000142	0.000768	CcSEcCtD
Dihydroergotamine—Anorexia—Epirubicin—stomach cancer	0.000142	0.000768	CcSEcCtD
Dihydroergotamine—Dyspnoea—Methotrexate—stomach cancer	0.000141	0.000767	CcSEcCtD
Dihydroergotamine—Somnolence—Methotrexate—stomach cancer	0.000141	0.000765	CcSEcCtD
Dihydroergotamine—Dizziness—Capecitabine—stomach cancer	0.000141	0.000765	CcSEcCtD
Dihydroergotamine—Dry mouth—Doxorubicin—stomach cancer	0.00014	0.00076	CcSEcCtD
Dihydroergotamine—Vomiting—Docetaxel—stomach cancer	0.00014	0.000759	CcSEcCtD
Dihydroergotamine—Dyspepsia—Methotrexate—stomach cancer	0.00014	0.000758	CcSEcCtD
Dihydroergotamine—Rash—Docetaxel—stomach cancer	0.000139	0.000753	CcSEcCtD
Dihydroergotamine—Hypotension—Epirubicin—stomach cancer	0.000139	0.000753	CcSEcCtD
Dihydroergotamine—Dermatitis—Docetaxel—stomach cancer	0.000139	0.000752	CcSEcCtD
Dihydroergotamine—Confusional state—Doxorubicin—stomach cancer	0.000139	0.000751	CcSEcCtD
Dihydroergotamine—Decreased appetite—Methotrexate—stomach cancer	0.000138	0.000748	CcSEcCtD
Dihydroergotamine—Headache—Docetaxel—stomach cancer	0.000138	0.000748	CcSEcCtD
Dihydroergotamine—Oedema—Doxorubicin—stomach cancer	0.000137	0.000745	CcSEcCtD
Dihydroergotamine—Fatigue—Methotrexate—stomach cancer	0.000137	0.000742	CcSEcCtD
Dihydroergotamine—Pain—Methotrexate—stomach cancer	0.000136	0.000736	CcSEcCtD
Dihydroergotamine—Vomiting—Capecitabine—stomach cancer	0.000136	0.000735	CcSEcCtD
Dihydroergotamine—Musculoskeletal discomfort—Epirubicin—stomach cancer	0.000135	0.000734	CcSEcCtD
Dihydroergotamine—Shock—Doxorubicin—stomach cancer	0.000135	0.000733	CcSEcCtD
Dihydroergotamine—Rash—Capecitabine—stomach cancer	0.000134	0.000729	CcSEcCtD
Dihydroergotamine—Insomnia—Epirubicin—stomach cancer	0.000134	0.000728	CcSEcCtD
Dihydroergotamine—Dermatitis—Capecitabine—stomach cancer	0.000134	0.000728	CcSEcCtD
Dihydroergotamine—Tachycardia—Doxorubicin—stomach cancer	0.000134	0.000727	CcSEcCtD
Dihydroergotamine—Headache—Capecitabine—stomach cancer	0.000134	0.000724	CcSEcCtD
Dihydroergotamine—Paraesthesia—Epirubicin—stomach cancer	0.000133	0.000723	CcSEcCtD
Dihydroergotamine—Hyperhidrosis—Doxorubicin—stomach cancer	0.000133	0.00072	CcSEcCtD
Dihydroergotamine—Dyspnoea—Epirubicin—stomach cancer	0.000132	0.000718	CcSEcCtD
Dihydroergotamine—Somnolence—Epirubicin—stomach cancer	0.000132	0.000716	CcSEcCtD
Dihydroergotamine—Anorexia—Doxorubicin—stomach cancer	0.000131	0.00071	CcSEcCtD
Dihydroergotamine—Nausea—Docetaxel—stomach cancer	0.000131	0.000709	CcSEcCtD
Dihydroergotamine—Feeling abnormal—Methotrexate—stomach cancer	0.000131	0.000709	CcSEcCtD
Dihydroergotamine—Dyspepsia—Epirubicin—stomach cancer	0.000131	0.000709	CcSEcCtD
Dihydroergotamine—Gastrointestinal pain—Methotrexate—stomach cancer	0.00013	0.000704	CcSEcCtD
Dihydroergotamine—Decreased appetite—Epirubicin—stomach cancer	0.000129	0.0007	CcSEcCtD
Dihydroergotamine—Hypotension—Doxorubicin—stomach cancer	0.000128	0.000696	CcSEcCtD
Dihydroergotamine—Fatigue—Epirubicin—stomach cancer	0.000128	0.000694	CcSEcCtD
Dihydroergotamine—Pain—Epirubicin—stomach cancer	0.000127	0.000689	CcSEcCtD
Dihydroergotamine—Nausea—Capecitabine—stomach cancer	0.000127	0.000687	CcSEcCtD
Dihydroergotamine—Urticaria—Methotrexate—stomach cancer	0.000126	0.000684	CcSEcCtD
Dihydroergotamine—Abdominal pain—Methotrexate—stomach cancer	0.000125	0.00068	CcSEcCtD
Dihydroergotamine—Body temperature increased—Methotrexate—stomach cancer	0.000125	0.00068	CcSEcCtD
Dihydroergotamine—Musculoskeletal discomfort—Doxorubicin—stomach cancer	0.000125	0.000679	CcSEcCtD
Dihydroergotamine—Insomnia—Doxorubicin—stomach cancer	0.000124	0.000674	CcSEcCtD
Dihydroergotamine—Paraesthesia—Doxorubicin—stomach cancer	0.000123	0.000669	CcSEcCtD
Dihydroergotamine—Dyspnoea—Doxorubicin—stomach cancer	0.000122	0.000664	CcSEcCtD
Dihydroergotamine—Feeling abnormal—Epirubicin—stomach cancer	0.000122	0.000664	CcSEcCtD
Dihydroergotamine—Somnolence—Doxorubicin—stomach cancer	0.000122	0.000663	CcSEcCtD
Dihydroergotamine—Gastrointestinal pain—Epirubicin—stomach cancer	0.000121	0.000659	CcSEcCtD
Dihydroergotamine—Dyspepsia—Doxorubicin—stomach cancer	0.000121	0.000656	CcSEcCtD
Dihydroergotamine—Decreased appetite—Doxorubicin—stomach cancer	0.000119	0.000648	CcSEcCtD
Dihydroergotamine—Fatigue—Doxorubicin—stomach cancer	0.000118	0.000643	CcSEcCtD
Dihydroergotamine—Urticaria—Epirubicin—stomach cancer	0.000118	0.00064	CcSEcCtD
Dihydroergotamine—Pain—Doxorubicin—stomach cancer	0.000117	0.000637	CcSEcCtD
Dihydroergotamine—Abdominal pain—Epirubicin—stomach cancer	0.000117	0.000637	CcSEcCtD
Dihydroergotamine—Body temperature increased—Epirubicin—stomach cancer	0.000117	0.000637	CcSEcCtD
Dihydroergotamine—Hypersensitivity—Methotrexate—stomach cancer	0.000117	0.000634	CcSEcCtD
Dihydroergotamine—Asthenia—Methotrexate—stomach cancer	0.000114	0.000618	CcSEcCtD
Dihydroergotamine—Feeling abnormal—Doxorubicin—stomach cancer	0.000113	0.000614	CcSEcCtD
Dihydroergotamine—Gastrointestinal pain—Doxorubicin—stomach cancer	0.000112	0.000609	CcSEcCtD
Dihydroergotamine—Pruritus—Methotrexate—stomach cancer	0.000112	0.000609	CcSEcCtD
Dihydroergotamine—Hypersensitivity—Epirubicin—stomach cancer	0.000109	0.000593	CcSEcCtD
Dihydroergotamine—Urticaria—Doxorubicin—stomach cancer	0.000109	0.000592	CcSEcCtD
Dihydroergotamine—Abdominal pain—Doxorubicin—stomach cancer	0.000109	0.000589	CcSEcCtD
Dihydroergotamine—Body temperature increased—Doxorubicin—stomach cancer	0.000109	0.000589	CcSEcCtD
Dihydroergotamine—Diarrhoea—Methotrexate—stomach cancer	0.000109	0.000589	CcSEcCtD
Dihydroergotamine—Asthenia—Epirubicin—stomach cancer	0.000107	0.000578	CcSEcCtD
Dihydroergotamine—Pruritus—Epirubicin—stomach cancer	0.000105	0.00057	CcSEcCtD
Dihydroergotamine—Dizziness—Methotrexate—stomach cancer	0.000105	0.000569	CcSEcCtD
Dihydroergotamine—Diarrhoea—Epirubicin—stomach cancer	0.000102	0.000551	CcSEcCtD
Dihydroergotamine—Hypersensitivity—Doxorubicin—stomach cancer	0.000101	0.000549	CcSEcCtD
Dihydroergotamine—Vomiting—Methotrexate—stomach cancer	0.000101	0.000547	CcSEcCtD
Dihydroergotamine—Rash—Methotrexate—stomach cancer	0.0001	0.000543	CcSEcCtD
Dihydroergotamine—Dermatitis—Methotrexate—stomach cancer	9.99e-05	0.000542	CcSEcCtD
Dihydroergotamine—Headache—Methotrexate—stomach cancer	9.94e-05	0.000539	CcSEcCtD
Dihydroergotamine—Asthenia—Doxorubicin—stomach cancer	9.86e-05	0.000535	CcSEcCtD
Dihydroergotamine—Dizziness—Epirubicin—stomach cancer	9.82e-05	0.000533	CcSEcCtD
Dihydroergotamine—Pruritus—Doxorubicin—stomach cancer	9.72e-05	0.000527	CcSEcCtD
Dihydroergotamine—Vomiting—Epirubicin—stomach cancer	9.44e-05	0.000512	CcSEcCtD
Dihydroergotamine—Nausea—Methotrexate—stomach cancer	9.42e-05	0.000511	CcSEcCtD
Dihydroergotamine—Diarrhoea—Doxorubicin—stomach cancer	9.4e-05	0.00051	CcSEcCtD
Dihydroergotamine—Rash—Epirubicin—stomach cancer	9.36e-05	0.000508	CcSEcCtD
Dihydroergotamine—Dermatitis—Epirubicin—stomach cancer	9.35e-05	0.000507	CcSEcCtD
Dihydroergotamine—Headache—Epirubicin—stomach cancer	9.3e-05	0.000505	CcSEcCtD
Dihydroergotamine—Dizziness—Doxorubicin—stomach cancer	9.08e-05	0.000493	CcSEcCtD
Dihydroergotamine—Nausea—Epirubicin—stomach cancer	8.82e-05	0.000478	CcSEcCtD
Dihydroergotamine—Vomiting—Doxorubicin—stomach cancer	8.73e-05	0.000474	CcSEcCtD
Dihydroergotamine—Rash—Doxorubicin—stomach cancer	8.66e-05	0.00047	CcSEcCtD
Dihydroergotamine—Dermatitis—Doxorubicin—stomach cancer	8.65e-05	0.000469	CcSEcCtD
Dihydroergotamine—Headache—Doxorubicin—stomach cancer	8.61e-05	0.000467	CcSEcCtD
Dihydroergotamine—Nausea—Doxorubicin—stomach cancer	8.16e-05	0.000443	CcSEcCtD
Dihydroergotamine—CYP3A4—Metabolism—FADS1—stomach cancer	1.12e-05	0.000138	CbGpPWpGaD
Dihydroergotamine—ABCB1—Transmembrane transport of small molecules—ALB—stomach cancer	1.12e-05	0.000138	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—ADRB2—stomach cancer	1.12e-05	0.000137	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling by GPCR—MAPK1—stomach cancer	1.11e-05	0.000137	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling by GPCR—EGFR—stomach cancer	1.11e-05	0.000137	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—ERCC2—stomach cancer	1.11e-05	0.000136	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling by GPCR—MAPK3—stomach cancer	1.1e-05	0.000135	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Hemostasis—KRAS—stomach cancer	1.1e-05	0.000135	CbGpPWpGaD
Dihydroergotamine—HTR6—GPCR downstream signaling—PIK3CA—stomach cancer	1.1e-05	0.000135	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—SERPINE1—stomach cancer	1.09e-05	0.000134	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—PPP2R1A—stomach cancer	1.09e-05	0.000134	CbGpPWpGaD
Dihydroergotamine—HTR1D—GPCR downstream signaling—PIK3CA—stomach cancer	1.09e-05	0.000133	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—SERPINE1—stomach cancer	1.09e-05	0.000133	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling by GPCR—KRAS—stomach cancer	1.08e-05	0.000133	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling by GPCR—KRAS—stomach cancer	1.07e-05	0.000132	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—IL6R—stomach cancer	1.07e-05	0.000131	CbGpPWpGaD
Dihydroergotamine—HTR1B—GPCR downstream signaling—PIK3CA—stomach cancer	1.06e-05	0.000131	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—CD44—stomach cancer	1.06e-05	0.000131	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—SERPINE1—stomach cancer	1.06e-05	0.000131	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—RHOA—stomach cancer	1.06e-05	0.00013	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—IRS2—stomach cancer	1.05e-05	0.000129	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—SREBF2—stomach cancer	1.05e-05	0.000129	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling by GPCR—KRAS—stomach cancer	1.05e-05	0.000129	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—RHOA—stomach cancer	1.05e-05	0.000129	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling by GPCR—MAPK1—stomach cancer	1.05e-05	0.000128	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling by GPCR—EGFR—stomach cancer	1.05e-05	0.000128	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—NOS3—stomach cancer	1.04e-05	0.000128	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—MTHFR—stomach cancer	1.04e-05	0.000128	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—RORA—stomach cancer	1.04e-05	0.000128	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling by GPCR—RHOA—stomach cancer	1.04e-05	0.000128	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—NOS3—stomach cancer	1.04e-05	0.000127	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—RHOA—stomach cancer	1.03e-05	0.000126	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—CAV1—stomach cancer	1.02e-05	0.000126	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—APOA1—stomach cancer	1.02e-05	0.000125	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—SMAD4—stomach cancer	1.02e-05	0.000125	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—NOS3—stomach cancer	1.01e-05	0.000125	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Hemostasis—PIK3CA—stomach cancer	1.01e-05	0.000124	CbGpPWpGaD
Dihydroergotamine—ADRA2A—GPCR downstream signaling—CXCL8—stomach cancer	1e-05	0.000123	CbGpPWpGaD
Dihydroergotamine—HTR2B—GPCR downstream signaling—PIK3CA—stomach cancer	1e-05	0.000123	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—SERPINE1—stomach cancer	9.99e-06	0.000123	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling by GPCR—PIK3CA—stomach cancer	9.95e-06	0.000122	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling by GPCR—KRAS—stomach cancer	9.88e-06	0.000121	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling by GPCR—PIK3CA—stomach cancer	9.87e-06	0.000121	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—ERBB2—stomach cancer	9.77e-06	0.00012	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Hemostasis—TP53—stomach cancer	9.76e-06	0.00012	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—ALDOB—stomach cancer	9.75e-06	0.00012	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—PRKCB—stomach cancer	9.73e-06	0.000119	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—ERBB2—stomach cancer	9.69e-06	0.000119	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—IL6ST—stomach cancer	9.69e-06	0.000119	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling by GPCR—PIK3CA—stomach cancer	9.67e-06	0.000119	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—FYN—stomach cancer	9.64e-06	0.000118	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—RHOA—stomach cancer	9.63e-06	0.000118	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—CAV1—stomach cancer	9.61e-06	0.000118	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—APOA1—stomach cancer	9.59e-06	0.000118	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—NOS3—stomach cancer	9.53e-06	0.000117	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—ERBB2—stomach cancer	9.49e-06	0.000117	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Hemostasis—HRAS—stomach cancer	9.33e-06	0.000115	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—APC—stomach cancer	9.31e-06	0.000114	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—CXCL8—stomach cancer	9.26e-06	0.000114	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling by GPCR—HRAS—stomach cancer	9.2e-06	0.000113	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—CXCL8—stomach cancer	9.19e-06	0.000113	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling by GPCR—HRAS—stomach cancer	9.13e-06	0.000112	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling by GPCR—CXCL8—stomach cancer	9.12e-06	0.000112	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling by GPCR—PIK3CA—stomach cancer	9.08e-06	0.000111	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—ALOX5—stomach cancer	9.06e-06	0.000111	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—FGFR2—stomach cancer	9.05e-06	0.000111	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—CDKN1B—stomach cancer	9.05e-06	0.000111	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—PPP2R1A—stomach cancer	9.04e-06	0.000111	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—CXCL8—stomach cancer	9e-06	0.000111	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—CDKN1B—stomach cancer	8.98e-06	0.00011	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling by GPCR—HRAS—stomach cancer	8.94e-06	0.00011	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling by GPCR—MAPK3—stomach cancer	8.92e-06	0.00011	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—DPYD—stomach cancer	8.92e-06	0.000109	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—ERBB2—stomach cancer	8.92e-06	0.000109	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—GSTP1—stomach cancer	8.87e-06	0.000109	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling by GPCR—IL6—stomach cancer	8.81e-06	0.000108	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—CDKN1B—stomach cancer	8.79e-06	0.000108	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—HMOX1—stomach cancer	8.75e-06	0.000107	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling by GPCR—IL6—stomach cancer	8.74e-06	0.000107	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—IL6R—stomach cancer	8.65e-06	0.000106	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—CCND1—stomach cancer	8.63e-06	0.000106	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—JUN—stomach cancer	8.61e-06	0.000106	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—CCND1—stomach cancer	8.56e-06	0.000105	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling by GPCR—IL6—stomach cancer	8.56e-06	0.000105	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—JUN—stomach cancer	8.55e-06	0.000105	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling by GPCR—MAPK1—stomach cancer	8.49e-06	0.000104	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling by GPCR—EGFR—stomach cancer	8.48e-06	0.000104	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—CXCL8—stomach cancer	8.46e-06	0.000104	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—PPARG—stomach cancer	8.45e-06	0.000104	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling by GPCR—HRAS—stomach cancer	8.4e-06	0.000103	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—CCND1—stomach cancer	8.39e-06	0.000103	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—MMP9—stomach cancer	8.38e-06	0.000103	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—JUN—stomach cancer	8.37e-06	0.000103	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—CDKN1A—stomach cancer	8.35e-06	0.000103	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—MMP9—stomach cancer	8.32e-06	0.000102	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—IRS2—stomach cancer	8.29e-06	0.000102	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—CDKN1A—stomach cancer	8.29e-06	0.000102	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—CDKN1B—stomach cancer	8.26e-06	0.000101	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—TYMS—stomach cancer	8.25e-06	0.000101	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—GSTM1—stomach cancer	8.15e-06	0.0001	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—MAPK8—stomach cancer	8.15e-06	0.0001	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—MMP9—stomach cancer	8.14e-06	0.0001	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—CDKN1A—stomach cancer	8.11e-06	9.96e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—GPCR downstream signaling—PIK3CA—stomach cancer	8.11e-06	9.96e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—SERPINE1—stomach cancer	8.1e-06	9.94e-05	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—MAPK8—stomach cancer	8.09e-06	9.93e-05	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling by GPCR—IL6—stomach cancer	8.04e-06	9.87e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—CAV1—stomach cancer	8.04e-06	9.87e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—APOA1—stomach cancer	8.02e-06	9.84e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling by GPCR—KRAS—stomach cancer	8.02e-06	9.84e-05	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—MAPK8—stomach cancer	7.92e-06	9.72e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—GSTT1—stomach cancer	7.88e-06	9.68e-05	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—CCND1—stomach cancer	7.88e-06	9.67e-05	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—JUN—stomach cancer	7.86e-06	9.65e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—RHOA—stomach cancer	7.81e-06	9.59e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—CYP2A6—stomach cancer	7.79e-06	9.57e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—NOS3—stomach cancer	7.73e-06	9.49e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—ERCC2—stomach cancer	7.66e-06	9.41e-05	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—MMP9—stomach cancer	7.65e-06	9.39e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—PRKCB—stomach cancer	7.65e-06	9.39e-05	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—CDKN1A—stomach cancer	7.62e-06	9.36e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—IL6ST—stomach cancer	7.62e-06	9.35e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—ALB—stomach cancer	7.6e-06	9.33e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—AKR1C3—stomach cancer	7.58e-06	9.31e-05	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—VEGFA—stomach cancer	7.52e-06	9.24e-05	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—VEGFA—stomach cancer	7.47e-06	9.17e-05	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—STAT3—stomach cancer	7.45e-06	9.15e-05	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—MAPK8—stomach cancer	7.44e-06	9.13e-05	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—STAT3—stomach cancer	7.39e-06	9.08e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—ENO1—stomach cancer	7.39e-06	9.07e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling by GPCR—PIK3CA—stomach cancer	7.36e-06	9.04e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—APC—stomach cancer	7.32e-06	8.99e-05	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—VEGFA—stomach cancer	7.31e-06	8.98e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—NOS3—stomach cancer	7.27e-06	8.92e-05	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—STAT3—stomach cancer	7.24e-06	8.89e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—ERBB2—stomach cancer	7.23e-06	8.88e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—MTHFR—stomach cancer	7.2e-06	8.85e-05	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—MAPK3—stomach cancer	7.12e-06	8.74e-05	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—MAPK3—stomach cancer	7.06e-06	8.67e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling by GPCR—MAPK3—stomach cancer	7.01e-06	8.61e-05	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—MYC—stomach cancer	6.92e-06	8.5e-05	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—MAPK3—stomach cancer	6.92e-06	8.49e-05	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—MYC—stomach cancer	6.87e-06	8.44e-05	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—VEGFA—stomach cancer	6.87e-06	8.43e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—CXCL8—stomach cancer	6.86e-06	8.42e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling by GPCR—HRAS—stomach cancer	6.81e-06	8.37e-05	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—STAT3—stomach cancer	6.8e-06	8.35e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—IL6R—stomach cancer	6.8e-06	8.35e-05	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—MAPK1—stomach cancer	6.77e-06	8.32e-05	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—EGFR—stomach cancer	6.77e-06	8.31e-05	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—MYC—stomach cancer	6.73e-06	8.26e-05	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—MAPK1—stomach cancer	6.72e-06	8.25e-05	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—EGFR—stomach cancer	6.72e-06	8.25e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—CDKN1B—stomach cancer	6.7e-06	8.22e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling by GPCR—MAPK1—stomach cancer	6.67e-06	8.19e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling by GPCR—EGFR—stomach cancer	6.67e-06	8.19e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—PTGS2—stomach cancer	6.65e-06	8.16e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—CAV1—stomach cancer	6.65e-06	8.16e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—APOA1—stomach cancer	6.63e-06	8.14e-05	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—MAPK1—stomach cancer	6.58e-06	8.08e-05	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—EGFR—stomach cancer	6.58e-06	8.08e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—CD44—stomach cancer	6.55e-06	8.05e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling by GPCR—IL6—stomach cancer	6.52e-06	8.01e-05	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—MAPK3—stomach cancer	6.5e-06	7.98e-05	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—KRAS—stomach cancer	6.4e-06	7.85e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—CCND1—stomach cancer	6.39e-06	7.84e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—JUN—stomach cancer	6.38e-06	7.83e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—GPCR downstream signaling—PIK3CA—stomach cancer	6.37e-06	7.83e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—SERPINE1—stomach cancer	6.36e-06	7.81e-05	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—KRAS—stomach cancer	6.35e-06	7.79e-05	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—MYC—stomach cancer	6.32e-06	7.76e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling by GPCR—KRAS—stomach cancer	6.3e-06	7.73e-05	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—KRAS—stomach cancer	6.22e-06	7.63e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—MMP9—stomach cancer	6.2e-06	7.62e-05	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—MAPK1—stomach cancer	6.18e-06	7.59e-05	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—EGFR—stomach cancer	6.18e-06	7.59e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—CDKN1A—stomach cancer	6.18e-06	7.59e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—RHOA—stomach cancer	6.14e-06	7.54e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—NOS3—stomach cancer	6.08e-06	7.46e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—MAPK8—stomach cancer	6.03e-06	7.41e-05	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—PIK3CA—stomach cancer	5.88e-06	7.22e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—PPARG—stomach cancer	5.84e-06	7.17e-05	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—KRAS—stomach cancer	5.84e-06	7.17e-05	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—PIK3CA—stomach cancer	5.83e-06	7.16e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling by GPCR—PIK3CA—stomach cancer	5.79e-06	7.11e-05	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—PIK3CA—stomach cancer	5.71e-06	7.01e-05	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—TP53—stomach cancer	5.69e-06	6.98e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—ERBB2—stomach cancer	5.68e-06	6.98e-05	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—TP53—stomach cancer	5.64e-06	6.93e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—PPP2R1A—stomach cancer	5.57e-06	6.84e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—VEGFA—stomach cancer	5.57e-06	6.84e-05	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—TP53—stomach cancer	5.52e-06	6.78e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—STAT3—stomach cancer	5.51e-06	6.77e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—GSTP1—stomach cancer	5.47e-06	6.71e-05	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—HRAS—stomach cancer	5.44e-06	6.68e-05	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—HRAS—stomach cancer	5.4e-06	6.62e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—HMOX1—stomach cancer	5.39e-06	6.62e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—CXCL8—stomach cancer	5.39e-06	6.62e-05	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—PIK3CA—stomach cancer	5.36e-06	6.59e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling by GPCR—HRAS—stomach cancer	5.35e-06	6.57e-05	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—HRAS—stomach cancer	5.28e-06	6.49e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—MAPK3—stomach cancer	5.27e-06	6.47e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—CDKN1B—stomach cancer	5.26e-06	6.46e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—ALB—stomach cancer	5.25e-06	6.45e-05	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—IL6—stomach cancer	5.2e-06	6.39e-05	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—TP53—stomach cancer	5.19e-06	6.37e-05	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—IL6—stomach cancer	5.16e-06	6.34e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling by GPCR—IL6—stomach cancer	5.13e-06	6.29e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—MYC—stomach cancer	5.12e-06	6.29e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—TYMS—stomach cancer	5.08e-06	6.24e-05	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—IL6—stomach cancer	5.06e-06	6.21e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—NOS3—stomach cancer	5.02e-06	6.17e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—GSTM1—stomach cancer	5.02e-06	6.17e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—CCND1—stomach cancer	5.02e-06	6.17e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—MAPK1—stomach cancer	5.01e-06	6.16e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—EGFR—stomach cancer	5.01e-06	6.15e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—JUN—stomach cancer	5.01e-06	6.15e-05	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—HRAS—stomach cancer	4.96e-06	6.09e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—MMP9—stomach cancer	4.87e-06	5.99e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—CDKN1A—stomach cancer	4.86e-06	5.96e-05	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—IL6—stomach cancer	4.75e-06	5.83e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—MAPK8—stomach cancer	4.74e-06	5.82e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—KRAS—stomach cancer	4.73e-06	5.81e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—ERCC2—stomach cancer	4.72e-06	5.8e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—PTGS2—stomach cancer	4.6e-06	5.64e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—MTHFR—stomach cancer	4.44e-06	5.45e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—VEGFA—stomach cancer	4.38e-06	5.37e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—PIK3CA—stomach cancer	4.35e-06	5.34e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—STAT3—stomach cancer	4.33e-06	5.32e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—TP53—stomach cancer	4.21e-06	5.17e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—MAPK3—stomach cancer	4.14e-06	5.08e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—CAV1—stomach cancer	4.09e-06	5.03e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—PIK3CA—stomach cancer	4.09e-06	5.02e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—APOA1—stomach cancer	4.08e-06	5.02e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—MYC—stomach cancer	4.03e-06	4.95e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—HRAS—stomach cancer	4.02e-06	4.94e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—MAPK1—stomach cancer	3.94e-06	4.84e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—EGFR—stomach cancer	3.94e-06	4.84e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—IL6—stomach cancer	3.85e-06	4.73e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—KRAS—stomach cancer	3.72e-06	4.57e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—PPARG—stomach cancer	3.6e-06	4.42e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—PIK3CA—stomach cancer	3.42e-06	4.2e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—TP53—stomach cancer	3.31e-06	4.06e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—ALB—stomach cancer	3.24e-06	3.97e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—HRAS—stomach cancer	3.16e-06	3.88e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—NOS3—stomach cancer	3.1e-06	3.8e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—IL6—stomach cancer	3.03e-06	3.72e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—PTGS2—stomach cancer	2.83e-06	3.48e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—PIK3CA—stomach cancer	2.83e-06	3.47e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—PIK3CA—stomach cancer	1.74e-06	2.14e-05	CbGpPWpGaD
